ライフサイエンスコーパス: bronchiolitis

1 severity of airflow limitation of those with bronchiolitis.

2 to decrease LOS in infants hospitalized with bronchiolitis.

3 use of acute lower respiratory infection and bronchiolitis.

4 two major causes of pediatric pneumonia and bronchiolitis.

5 for infants admitted to hospital with viral bronchiolitis.

6 f 2615 enrolled children, 1764 (67%) had RSV bronchiolitis.

7 biome profiles, and severity in infants with bronchiolitis.

8 mic load are at a higher risk of more-severe bronchiolitis.

9 nomic load had a higher risk for more-severe bronchiolitis.

10 y disease (OAD), a correlate of obliterative bronchiolitis.

11 ple of healthy infants hospitalized with RSV bronchiolitis.

12 lic acid-containing prescriptions and infant bronchiolitis.

13 hospitalization threshold for patients with bronchiolitis.

14 tonic saline (HS) for the acute treatment of bronchiolitis.

15 tional supplement recommendations for infant bronchiolitis.

16 for subsequent susceptibly to pneumonia and bronchiolitis.

17 schedule) in infants hospitalized with acute bronchiolitis.

18 mbled the histological pattern of follicular bronchiolitis.

19 months of age) with moderate-to-severe acute bronchiolitis.

20 ponse to RSV infection seen in children with bronchiolitis.

21 hospital discharge in patients with hypoxic bronchiolitis.

22 c histologic acute rejection and lymphocytic bronchiolitis.

23 among infants with a first episode of acute bronchiolitis.

24 eroid use in infants with a first episode of bronchiolitis.

25 f airway microbiota and CCL5 in infants with bronchiolitis.

26 ght the role of LL-37 in the pathogenesis of bronchiolitis.

27 udy of infants (age <1 yr) hospitalized with bronchiolitis.

28 s with COPD with emphysema that is absent in bronchiolitis.

29 s were associated with decreased severity in bronchiolitis.

30 ergency department with a diagnosis of acute bronchiolitis.

31 e patient was suspected to have eosinophilic bronchiolitis.

32 t associated with a poor clinical outcome in bronchiolitis.

33 infants and young children with acute viral bronchiolitis?

34 We observed that in emphysema (but not in bronchiolitis) (1) up-regulated genes were enriched in o

35 hile 30%-70% of RSV-infected infants develop bronchiolitis, 2% require hospitalization.

36 alization rates by census tract quintile for bronchiolitis (32.8, 20.8, 14.0, 10.4, and 5.1 per 1000)

37 ratory infection, croup, asthma, bronchitis, bronchiolitis, a wheezy lower respiratory infection or f

38 o 38.4% (P < .001), with no difference in ED bronchiolitis admission or ED revisit/readmission rates.

39 Viral bronchiolitis affects 20%-30% of infants; because there

40 y epithelium play a key role in constrictive bronchiolitis after lung transplantation, the typical ha

41 interleukin 10 (IL-10) were elevated in RSV+ bronchiolitis (all P < .05), furthermore CCL5 and IL-10

42 pitalizations per 1000 children per year for bronchiolitis and 1.6 (range across census tracts, 0-4.3

43 in 465 White children hospitalized with RSV bronchiolitis and 930 White population controls from the

44 SV) is the most important cause of infantile bronchiolitis and a major pathogen in elderly and immuno

45 s than 24 months with their first episode of bronchiolitis and a Respiratory Distress Assessment Inst

46 Despite viral clearance, bronchiolitis and alveolitis persisted at day 14 postinf

47 for covariates associated with pneumonia and bronchiolitis and bacterial airway colonization.

48 nger than 2 years who were hospitalized with bronchiolitis and children younger than 18 years who wer

49 roll children aged <2 years hospitalized for bronchiolitis and collect nasopharyngeal aspirates.

50 erential expression and gene coexpression in bronchiolitis and emphysema.

51 irus (RSV) is the leading cause of pediatric bronchiolitis and hospitalizations.

52 Infants with bronchiolitis and persistent respiratory distress after

53 nza virus (PIV) in humans is associated with bronchiolitis and pneumonia and can be especially proble

54 Bronchiolitis and pneumonia are leading causes of pediat

55 We calculated bronchiolitis and pneumonia hospitalization rates for Ha

56 Bronchiolitis and pneumonia hospitalization rates varied

57 he respiratory tract and is a major cause of bronchiolitis and pneumonia in children and the elderly.

58 tial virus (RSV) is the most common cause of bronchiolitis and pneumonia in infants and the elderly w

59 ) are two closely related viruses that cause bronchiolitis and pneumonia in infants and the elderly(1

60 ncytial virus (hRSV) is the leading cause of bronchiolitis and pneumonia in young children worldwide.

61 3) are major viral agents of acute pediatric bronchiolitis and pneumonia worldwide that lack vaccines

62 zed by epithelial desquamation, neutrophilic bronchiolitis and pneumonia, and obstructive pulmonary m

63 cute respiratory infection (ARI), especially bronchiolitis and pneumonia, in children worldwide.

64 virus (RSV) is a leading cause of childhood bronchiolitis and pneumonia, particularly in early infan

65 RSV) is the most frequent cause of infantile bronchiolitis and pneumonia.

66 into novel therapeutic approaches for viral bronchiolitis and pneumonia.

67 n disease, as RSV is a major cause of infant bronchiolitis and polymorphisms in the IFN system are kn

68 eased infiltration of the virus, lymphocytic bronchiolitis and reduced survival of Pgam5 (-/-) mice.

69 In this study, we induced obliterative bronchiolitis and studied the contribution of regulatory

70 reg cell expansion to protect against severe bronchiolitis and subsequent asthma.

71 ection in the absence of TLR7 predisposes to bronchiolitis and the inception of asthma.

72 viable future therapy for severe RSV-induced bronchiolitis and thereby prevent the inception of subse

73 re associated with disease severity in acute bronchiolitis and to evaluate whether detected viruses m

74 d 4 weeks to 12 months with mild to moderate bronchiolitis and true oxygen saturations of 88% or high

75 ion of serum LL-37 levels to the severity of bronchiolitis and viral etiology.

76 caused by a combination of airways disease (bronchiolitis) and parenchymal destruction (emphysema),

77 r/infrequent wheeze, maternal asthma, infant bronchiolitis, and atopic dermatitis were associated wit

78 redisposition to bronchopulmonary dysplasia, bronchiolitis, and childhood asthma.

79 refore, we clinically diagnosed eosinophilic bronchiolitis, and immediately administered oral prednis

80 mphocytic interstitial pneumonia, follicular bronchiolitis, and light-chain deposition disease are in

81 n, presenting with symptoms including croup, bronchiolitis, and pneumonia.

82 associated with higher risk of pneumonia and bronchiolitis, and this increased risk was likewise decr

83 Hospitalizations of infants for bronchiolitis are common and costly.

84 tions, 18 (24%) had an unscheduled visit for bronchiolitis as compared with 11 of the 43 infants with

85 Five studies carried out after bronchiolitis at less than 24 months of age, with a foll

86 ively followed 166 children hospitalized for bronchiolitis at less than 6 months of age until 5-7 yea

87 After bronchiolitis at less than 6 months of age, the risk of

88 monary edema in severe cases to constrictive bronchiolitis, being a more distant consequence.

89 diagnosis (HR=1.23; 95% CI: 0.97, 1.55) and bronchiolitis/bronchitis (HR=1.13; 95% CI: 0.99, 1.30).

90 l A pregnancy level and increased asthma and bronchiolitis/bronchitis rates in childhood were consist

91 here is definitive evidence that RSV-induced bronchiolitis can damage the airways to promote airway o

92 Implementation of a new bronchiolitis care process encouraging use of an OU-HOT

93 espiratory syncytial virus caused 66% of the bronchiolitis cases, and nearly half of the patients wer

94 Histology confirmed a constrictive form of bronchiolitis caused by expansion of microvascular-rich

95 Bronchiolitis causes substantial disease in young childr

96 h of the emphasis of the last few decades of bronchiolitis clinical care and research has centered on

97 Acute rejection, lymphocytic bronchiolitis, colonization with pseudomonas, infection,

98 ns similar to those typical for obliterative bronchiolitis developed in vivo after reconstitution wit

99 ster only" group had higher relative odds of bronchiolitis diagnosis (adjusted odds ratio = 1.17, 95%

100 Overall, 21% of infants had a bronchiolitis diagnosis, and 5% were hospitalized.

101 ty in testing and treatment of children with bronchiolitis, diagnostic testing rarely improves care,

102 try monitoring of nonhypoxemic patients with bronchiolitis did not shorten hospital length of stay an

103 y tree and can cause tracheitis, bronchitis, bronchiolitis, diffuse alveolar damage with pulmonary ed

104 In infants hospitalized with acute bronchiolitis, disease severity was not associated with

105 rosolized particles produced by infants with bronchiolitis due to RSV was measured using viable impac

106 1005 infants (age <1 year) hospitalized for bronchiolitis during 2011-2014, we observed statisticall

107 n 2 years of age or younger hospitalized for bronchiolitis during the period from 2009 to 2014 at 1 o

108 alized for respiratory syncytial virus (RSV) bronchiolitis every year.

109 The majority of infants with mild bronchiolitis experienced recurrent or sustained desatur

110 d with differential susceptibility to severe bronchiolitis following infection with respiratory syncy

111 Acute bronchiolitis frequently causes infant hospitalization.

112 as the number of episodes with pneumonia and bronchiolitis from 0 to 3 years of age.

113 A total of 692 patients with bronchiolitis from the 2010-2011 bronchiolitis season we

114 1_C allele was also more frequent in the RSV bronchiolitis group compared with controls (OR 1.12, 95%

115 icacy of 3% Hypertonic Saline in Acute Viral Bronchiolitis (GUERANDE) study was a multicenter, double

116 Infants with severe RSV bronchiolitis had increased plasma cytokine concentratio

117 Although acute rejection and lymphocytic bronchiolitis have been identified as risk factors for t

118 hospital length of stay (LOS) in acute viral bronchiolitis have suggested benefit.

119 There were 1495 bronchiolitis hospitalizations and 1231 pneumonia hospit

120 s were collected from 363 infants with acute bronchiolitis in a randomized, controlled trial that com

121 dren (93% White) hospitalized for severe RSV bronchiolitis in Boston and 333 parents into a follow-up

122 of age of children who were hospitalized for bronchiolitis in early infancy.

123 ovirus infection alone predisposed to severe bronchiolitis in early life and subsequent asthma in lat

124 ociated with increased risk of pneumonia and bronchiolitis in early life independently of asthma.

125 the risk of childhood asthma, pneumonia, and bronchiolitis in genetically susceptible subjects.

126 lotype carriage may increase the risk of RSV bronchiolitis in infancy and subsequent asthma developme

127 a VDBP haplotype and hospitalization for RSV bronchiolitis in infancy in two independent cohorts.

128 Respiratory syncytial virus (RSV) bronchiolitis in infancy is a major risk factor for recu

129 Acute bronchiolitis in infants frequently results in hospitali

130 In the treatment of acute bronchiolitis in infants, inhaled racemic adrenaline is

131 s (RSV) infection is the number one cause of bronchiolitis in infants, yet no vaccines are available

132 V) is the most common cause of serious viral bronchiolitis in infants, young children, and the elderl

133 ore patients experiencing severe lymphocytic bronchiolitis in RAS compared with BOS (P=0.031).

134 HS does not appear to be indicated to treat bronchiolitis in the acute care setting.

135 Hypertonic saline given to children with bronchiolitis in the ED decreases hospital admissions.

136 %) subsequent unscheduled medical visits for bronchiolitis in the true oximetry group and 15 of 105 (

137 rways of pediatric patients with RSV-induced bronchiolitis in vast numbers: approximately 80% of infi

138 virus (RSV) infection is the major cause of bronchiolitis in young children.

139 ociated with susceptibility to pneumonia and bronchiolitis in young children.

140 etapneumovirus (hMPV) is a frequent cause of bronchiolitis in young children.

141 y outcome was unscheduled medical visits for bronchiolitis, including a visit to any health care prof

142 pital admissions for asthma, bronchitis, and bronchiolitis (International Classification of Diseases,

143 ospital admission for asthma, bronchitis and bronchiolitis (International Classification of Diseases,

144 Respiratory bronchiolitis-interstitial lung disease is now commonly

145 Viral bronchiolitis is a common clinical syndrome affecting in

146 Bronchiolitis is a common condition in children less tha

147 Respiratory syncytial virus-bronchiolitis is a major independent risk factor for sub

148 of neutrophils in patients with RSV-induced bronchiolitis is best performed under the umbrella of an

149 Bronchiolitis is one of the most common and costly respi

150 Acute bronchiolitis is the leading cause of hospitalization am

151 RATIONALE: Bronchiolitis is the most common lower respiratory infec

152 Acute bronchiolitis is the most frequent lower respiratory tra

153 al, acute and chronic rejection, lymphocytic bronchiolitis (LB), and respiratory infection after lung

154 ng transplantation, may promote obliterative bronchiolitis leading to graft failure in lung transplan

155 lticenter study of infants hospitalized with bronchiolitis, lower levels of serum LL-37 were associat

156 oximetry has been associated with changes in bronchiolitis management and may have lowered the hospit

157 philic airway inflammation in a murine viral bronchiolitis model, demonstration of similar effects in

158 Daily counts of ED visits for bronchitis and bronchiolitis (n = 80,399), pneumonia (n = 63,359), and

159 In children with viral bronchiolitis, nasal propionate levels were decreased an

160 to 12 months of age with physician-diagnosed bronchiolitis newly admitted into eight paediatric hospi

161 he first time that infants with RSV-positive bronchiolitis nursed in a ward setting or ventilated in

162 Obliterative bronchiolitis (OB) is a clinical syndrome marked by prog

163 Obliterative bronchiolitis (OB) is the primary cause of late morbidit

164 Obliterative bronchiolitis (OB) post-lung transplantation involves IL

165 ansplant survival is limited by obliterative bronchiolitis (OB), but the mechanisms of OB development

166 -airway histological process of obliterative bronchiolitis (OB).

167 brosis in lung and skin leads to progressive bronchiolitis obliterans (BO) and scleroderma, respectiv

168 Given the impact of T cells on bronchiolitis obliterans (BO) in lung transplantation, w

169 Bronchiolitis obliterans (BO) is a detrimental late pulm

170 g-term outcome of lung transplantation, with bronchiolitis obliterans (BO) representing the predomina

171 use of the associations between diacetyl and bronchiolitis obliterans and other severe respiratory di

172 Idiopathic pneumonia syndrome (IPS) and bronchiolitis obliterans are now recognized as part of a

173 thelial and intraluminal fibrotic lesions of bronchiolitis obliterans by day 28.

174 osttransplantation course was complicated by bronchiolitis obliterans from chronic rejection and by r

175 Experimental models of IPS and bronchiolitis obliterans have proven useful to test stra

176 s were identified to show histopathology for bronchiolitis obliterans in all allogeneic grafts.

177 In a different cGVHD model, in which bronchiolitis obliterans is a prominent manifestation, F

178 Bronchiolitis obliterans is the leading cause of chronic

179 bronchiolitis obliterans syndrome (BOS), and bronchiolitis obliterans organizing pneumonia (BOOP).

180 antly elevated within 3 months of developing bronchiolitis obliterans syndrome (8.3 [1.4-25.1] vs. 3.

181 emic steroids are the standard treatment for bronchiolitis obliterans syndrome (BOS) after allogeneic

182 In past years, a diagnosis of bronchiolitis obliterans syndrome (BOS) after allogeneic

183 Bronchiolitis obliterans syndrome (BOS) after lung trans

184 Using log-rank test, freedom from bronchiolitis obliterans syndrome (BOS) and graft surviv

185 d for multiorgan system cGVHD and associated bronchiolitis obliterans syndrome (BOS) in a murine mode

186 lowing lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

187 after lung transplantation fails to prevent bronchiolitis obliterans syndrome (BOS) in many patients

188 Bronchiolitis obliterans syndrome (BOS) is the primary l

189 allograft dysfunction (CLAD), presenting as bronchiolitis obliterans syndrome (BOS) or restrictive a

190 n (AR) and development of chronic rejection, bronchiolitis obliterans syndrome (BOS) remain major lim

191 Bronchiolitis obliterans syndrome (BOS), a condition of

192 gnized, idiopathic pneumonia syndrome (IPS), bronchiolitis obliterans syndrome (BOS), and bronchiolit

193 tive (ELR(+)) CXC chemokines associated with bronchiolitis obliterans syndrome (BOS), but the effect

194 ween these disorders and risk for subsequent bronchiolitis obliterans syndrome (BOS), mortality and g

195 Bronchiolitis obliterans syndrome (BOS), pathognomonic f

196 Bronchiolitis obliterans syndrome (BOS), the major cause

197 irreversible decline in lung function termed bronchiolitis obliterans syndrome (BOS).

198 splantation may contribute to development of bronchiolitis obliterans syndrome (BOS).

199 The primary endpoint was freedom from bronchiolitis obliterans syndrome (BOS).

200 The per-protocol analysis shows incidence of bronchiolitis obliterans syndrome (BOS): 1/43 in the Eve

201 Secondary outcomes included freedom from bronchiolitis obliterans syndrome (fBOS) and rates of ac

202 rvival (P = 0.09) and increased freedom from bronchiolitis obliterans syndrome (P = 0.03) was observe

203 ar that patients may develop an obstructive (bronchiolitis obliterans syndrome [BOS]) or a restrictiv

204 Different clinical phenotypes (bronchiolitis obliterans syndrome [BOS]-neutrophilic BOS

205 smatch model of multiorgan system cGVHD with bronchiolitis obliterans syndrome and a minor MHC mismat

206 study was to investigate the development of bronchiolitis obliterans syndrome and graft loss after L

207 Because current literature suggests bronchiolitis obliterans syndrome and restrictive allogr

208 rom lung transplant recipients who developed bronchiolitis obliterans syndrome and were compared to s

209 condary end points were overall survival and bronchiolitis obliterans syndrome at 2 years.

210 sinophilic BAL predisposed to development of bronchiolitis obliterans syndrome but particularly to re

211 pha as a potential new therapeutic target in bronchiolitis obliterans syndrome deserving of a randomi

212 survival in a multivariable model including bronchiolitis obliterans syndrome grade and baseline FEV

213 Bronchiolitis obliterans syndrome has been associated wi

214 o activate fibroblasts in the development of bronchiolitis obliterans syndrome has not been evaluated

215 after heart transplantation, and potentially bronchiolitis obliterans syndrome in lung transplant rec

216 Bronchiolitis obliterans syndrome is caused by a fibropr

217 Bronchiolitis obliterans syndrome is characterized by fi

218 and were divided into three groups: no CLAD (bronchiolitis obliterans syndrome level 0 [BOS 0]), earl

219 onic lung allograft dysfunction manifests as bronchiolitis obliterans syndrome or the recently descri

220 was not a risk factor for the development of bronchiolitis obliterans syndrome or worse overall survi

221 Freedom from bronchiolitis obliterans syndrome was lower, and mortali

222 Of the 22 patients (5%) who experienced bronchiolitis obliterans syndrome, 15 (6%) were in the a

223 e hypertension, renal dysfunction, diabetes, bronchiolitis obliterans syndrome, and malignancy.

224 tervention in five patients with progressive bronchiolitis obliterans syndrome, anti-TNFalpha treatme

225 s that CMVIG prophylaxis reduces the risk of bronchiolitis obliterans syndrome, but a controlled tria

226 Among lung transplant recipients, "bronchiolitis obliterans syndrome," a disorder with clin

227 nd 30-day mortality, follow-up survival, and bronchiolitis obliterans syndrome-free survival.

228 lantation imitate the in vivo development of bronchiolitis obliterans syndrome-like lesions and revea

229 reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

230 n of epithelial to mesenchymal transition in bronchiolitis obliterans syndrome.

231 ortality after lung transplantation (LTX) is bronchiolitis obliterans syndrome.

232 ng transplant patients prior to diagnosis of bronchiolitis obliterans syndrome.

233 defined as idiopathic pneumonia syndrome or bronchiolitis obliterans syndrome.

234 ociated with an increased risk of developing bronchiolitis obliterans syndrome.

235 ted rejection, acute cellular rejection, and bronchiolitis obliterans syndrome; however, the signific

236 rgan system, nonsclerodermatous disease with bronchiolitis obliterans where cGVHD is dependent on ant

237 in treating patients with panbronchiolitis, bronchiolitis obliterans, and rejection after lung trans

238 arget tissue that results in scleroderma and bronchiolitis obliterans, diagnostic features of cGVHD.

239 and pulmonary dysfunction characteristic of bronchiolitis obliterans.

240 ure is small airway obstruction arising from bronchiolitis obliterans.

241 ssue fibrosis manifesting as scleroderma and bronchiolitis obliterans.

242 ces epithelial injury via TGF-beta in murine bronchiolitis obliterans; that TGF-beta and the C' casca

243 ver, some respiratory viral infections cause bronchiolitis of infancy and childhood wheeze, and can e

244 ght paediatric hospital units in the UK (the Bronchiolitis of Infancy Discharge Study [BIDS]).

245 lt mice, pDC depletion predisposed to severe bronchiolitis only after antibiotic treatment.

246 ry) weeks of age, and pathologic features of bronchiolitis or asthma were assessed.

247 ve cohort study in infants hospitalized with bronchiolitis over 3 winters (2011-2014).

248 tions (A>/=2; both P<0.0001) and lymphocytic bronchiolitis (P=0.0006) in BOS and RAS versus control.

249 microbiota plays an important role in viral bronchiolitis pathobiology.

250 osed asthma was present in 13% of the former bronchiolitis patients at 11-13 years of age.

251 ase in children and is associated with acute bronchiolitis, pneumonia, and asthma exacerbations, yet

252 24 months with a primary diagnosis of viral bronchiolitis presenting to the ED of 2 urban free-stand

253 naging infants and children hospitalized for bronchiolitis recommend only obtaining intermittent or "

254 and very young, with some infants developing bronchiolitis, recurrent wheezing, and asthma following

255 cept study azithromycin treatment during RSV bronchiolitis reduced upper airway IL-8 levels, prolonge

256 te whether azithromycin treatment during RSV bronchiolitis reduces serum and nasal lavage IL-8 levels

257 omized clinical trials of HS in infants with bronchiolitis reporting LOS as an outcome measure were i

258 ients with respiratory syncytial virus (RSV) bronchiolitis requiring admission to the pediatric inten

259 acute rejection and small-airway lymphocytic bronchiolitis, respectively.

260 independent populations of infants with RSV bronchiolitis revealed that the severity of RSV infectio

261 -37 levels and the most common virus causing bronchiolitis, RSV.

262 tients with bronchiolitis from the 2010-2011 bronchiolitis season were compared with 725 patients fro

263 rial on 2 parallel groups conducted during 2 bronchiolitis seasons (October through March) from Octob

264 ndomized clinical trial during 3 consecutive bronchiolitis seasons from March 1, 2008, through April

265 hods are flawed, particularly in a pediatric bronchiolitis setting.

266 etabolome profiles significantly differed by bronchiolitis severity (P < 0.001).

267 ate the potential of metabolomics to predict bronchiolitis severity and better understand microbe-hos

268 ines significantly associated with decreased bronchiolitis severity are classified in a wide range of

269 ciations of the upper-airway microbiome with bronchiolitis severity, little is known about the mechan

270 This case suggests that eosinophilic bronchiolitis should be taken into consideration for dif

271 fine haplotypes GC1s, GC1f, and GC2, and RSV bronchiolitis susceptibility and subsequent asthma.

272 identification of subgroups of children with bronchiolitis that may benefit from focused clinical int

273 ated with a progressive form of constrictive bronchiolitis that targets conducting airways while spar

274 te the high incidence and resource burden of bronchiolitis, the mainstay of treatment remains support

275 For patients admitted with bronchiolitis, the use of deep suctioning in the first 2

276 n emergency department with mild to moderate bronchiolitis, those with an artificially elevated pulse

277 Management of infants with bronchiolitis to an oxygen saturation target of 90% or h

278 unknown how implementation of a hospitalwide bronchiolitis treatment protocol promoting OU-HOT would

279 is, four as sarcoidosis, four as respiratory bronchiolitis, two as organising pneumonia, and 18 as su

280 Severity of bronchiolitis was defined by intensive care use and hosp

281 nical outcome in respiratory syncytial virus bronchiolitis was studied in BALB/c mice.

282 To account for potential confounding by bronchiolitis, we used exacerbations/hospitalizations af

283 lonization, acute rejection, and lymphocytic bronchiolitis were compared between BOS, RAS, and stable

284 rgency department with signs and symptoms of bronchiolitis were eligible for enrollment.

285 One hundred eleven children with bronchiolitis were enrolled.

286 Twenty-four infants with bronchiolitis were recruited: 12 were respiratory syncyt

287 ined RSV in the air surrounding infants with bronchiolitis were sufficiently small to remain airborne

288 l virus (RSV) is the main causative agent of bronchiolitis, whereas rhinovirus (RV) is most commonly

289 SV) is the leading global cause of infantile bronchiolitis, which is associated with recurrent wheeze

290 n oxygen saturation of 90% for children with bronchiolitis, which is consistent with the WHO recommen

291 ent of infants and children hospitalized for bronchiolitis who show clinical improvement.

292 a first episode of acute moderate to severe bronchiolitis who were admitted to the pediatric ED rela

293 erwise healthy infants hospitalized with RSV bronchiolitis who were treated with azithromycin or plac

294 ts with respiratory failure because of viral bronchiolitis, who received either a PE-formula (n = 8)

295 wever, it remains unclear which infants with bronchiolitis will develop severe illness.

296 episode of respiratory syncytial virus (RSV) bronchiolitis with bacterial superinfection secondary to

297 inclusion, 777 with a first episode of acute bronchiolitis with respiratory distress and no chronic m

298 r understanding of the viral epidemiology of bronchiolitis, with increasing recognition of viruses ot

299 department stay, and unscheduled visits for bronchiolitis within 72 hours.

300 Clinical information on pneumonia and bronchiolitis within the first 3 years of life was prosp